Literature DB >> 21624085

Removal of doripenem during hemodialysis and the optimum dosing regimen for patients undergoing hemodialysis.

Kazutaka Tanoue1, Kazuhiko Nishi, Daisuke Kadowaki, Sumio Hirata.   

Abstract

The removal of doripenem by hemodialysis was studied in six hemodialysis patients. Following an intravenous drip infusion of 0.5 g of doripenem, plasma concentrations of the drug were measured. The decrease in drug concentrations in plasma was observed during various periods of non-hemodialysis, and hemodialysis accelerated the elimination of doripenem. For example, the calculated mean half-life during hemodialysis was significantly shorter than that during non-hemodialysis periods (P = 0.002). The calculated pharmacokinetic parameters indicated that the mean rate of decrease in plasma concentration due to hemodialysis alone was 56.12 ± 8.11%. Upon obtaining these results and several pharmacokinetic parameters, we attempted to optimize the dosing regimen of doripenem for hemodialysis patients. We recommend the use of 0.25 g of doripenem once a day in patients infected with viable bacteria, and in patients who are infected with Pseudomonas aeruginosa, 0.5 g twice a day on the first day of administration, followed by 0.5 g once a day.
© 2011 The Authors. Therapeutic Apheresis and Dialysis © 2011 International Society for Apheresis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21624085     DOI: 10.1111/j.1744-9987.2011.00914.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  3 in total

1.  Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy.

Authors:  M G Vossen; L Ehmann; S Pferschy; A Maier-Salamon; M Haidinger; C Weiser; J M Wenisch; K Saria; C Kajahn; S Jilch; R Lemmerer; M Bécède; M Zeitlinger; C Kloft; W Jäger; F Thalhammer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

2.  In vivo evaluation of drug dialyzability in a rat model of hemodialysis.

Authors:  Masaki Fukunaga; Daisuke Kadowaki; Mika Mori; Satomi Hagiwara; Yuki Narita; Junji Saruwatari; Ryota Tanaka; Hiroshi Watanabe; Keishi Yamasaki; Kazuaki Taguchi; Hiroki Ito; Toru Maruyama; Masaki Otagiri; Sumio Hirata
Journal:  PLoS One       Date:  2020-06-12       Impact factor: 3.240

Review 3.  Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.

Authors:  Lu Li; Xin Li; Yanzhe Xia; Yanqi Chu; Haili Zhong; Jia Li; Pei Liang; Yishan Bu; Rui Zhao; Yun Liao; Ping Yang; Xiaoyang Lu; Saiping Jiang
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.